BANK VONTOBEL/CALL/ELI LILLY & CO/740/0.1/21.06.24 | Delayed Deutsche Boerse AG 01:45:41 2024-06-21 pm EDT | ||
| 13.54 EUR | +5.95% |
|
| Current month | +73.64% | ||
| 1 month | +157.14% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 13.54 | +5.95% |
| 24-06-20 | 12.78 | -11.86% |
| 24-06-19 | 14.5 | +5.53% |
| 24-06-18 | 13.74 | -2.69% |
| 24-06-17 | 14.12 | +6.49% |
Delayed Quote Deutsche Boerse AG
Last update June 21, 2024 at 01:45 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VM345C |
| ISIN | DE000VM345C5 |
| Date issued | 2023-10-17 |
| Strike | 740 $ |
| Maturity | Today (-0 Days) |
| Parity | 10 : 1 |
| Emission price | 2.91 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.97 € |
|---|---|
| Lowest since issue | 0.95 € |
| Spread | 0.23 € |
| Spread % | 1.67% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
886
USD
Average target price
855.4
USD
Spread / Average Target
-3.45%
- Stock Market
- Warrants
- Warrant
